Shortly after the new coronavirus began to spread around the world, lesser-known vaccine developer Modana began working with the National Institutes of Health to create vaccines using new technologies.
The vaccine is now one of the pillars of the US COVID-19 response, with 130 million doses just six months after regulators approved the use of the vaccine.
Moderna is currently testing vaccines in young people and may need them in the future, along with vaccines and treatment of other illnesses, using a similar technology based on the genetic code called messenger RNA. I’m testing a booster.
The Associated Press spoke with President Stephen Hoge, who oversees Moderna’s investigation.
Q: Will I need a COVID-19 booster shot in the future?
A: I think there is a need for chronic boosters. I definitely think they are wise to plan. None of us want to be in the November situation next year when we need to go into another blockade. We will update the vaccine to ensure your backup is backed up. This is the variant booster that will be available in the fourth quarter.
Q: How long does it take to develop a new vaccine to fight the variant?
A: In the first version of the vaccine, we did it in about 5 months, but we had to do a large clinical trial. You don’t have to do that now. For boosters that target variants, you can do that in about three months.
Q: What makes messenger RNA so useful?
A: Messenger RNA is really just an instruction manual. It’s no longer a medicine made by someone. It’s an instruction to your body. You can put everything you need, such as the COVID-19 virus spelomers, into the manual and tell you what to make. If you want to change the paragraph, just cut and paste.
Q: What else can mRNA treat?
A: There are no illnesses that you should not be able to take medicine in the end.
Q: What are you working on?
(Vaccine) Viruses such as influenza and cytomegalovirus, and other viruses such as HIV that are difficult to track. Half of our pipeline is in treatment. There are cancer and heart disease programs.
Q: What will MODERNA do 10 years from now?
Focus on cancer, infectious diseases, and autoimmune diseases. For cancer, there are several programs in the mid-term study. We are working to prevent the recurrence of melanoma. We are partnering with AstraZeneca to develop messenger RNA that can be injected into people undergoing coronary artery bypass grafting to grow heart cells. If it can be done, it will bring about change.
Suggest a fix
Moderna president talks about COVID-19 and vaccine technology | WGN Radio 720
Source link Moderna president talks about COVID-19 and vaccine technology | WGN Radio 720